Search

The effect of nuclear stimulators and inhibitors on the nuclear contents of nucleoplasmic antigens (ENA) was studied by the indirect immunofluorescence technique. Human autoimmune sera, one reacting with RNase-A-sensitive and one with RNase-A-resistant components of ENA in the passive haemagglutination test, were used as indicators of the RNP and Sm antigens, respectively. Phytohaemagglutinin and concanavalin A both caused an accumulation of these antigens in normal blood lymphocytes. With pokeweed mitogen, staphylococcal protein A, or purified protein derivative the accumulation was apparently restricted to B cells, alpha-amanitine, 10 microgram/ml, prevented the mitogen-induced accumulation of RNP in normal human blood lymphocytes and reduced the contents of this antigen in several lymphoblastoid cell lines and in HeLa cells but did not significantly affect the contents of Sm antigen in any of these cell types. The experimental results suggest that the RNP and Sm nucleoplasmic antigens are normal rapid-phase reactants integrated in physiological nuclear mechanisms rather than inert structural constituents of the nuclear matrix or the products of a latent virus.

The nucleoplasmic autoantigens RNP and Sm are of particular interest because of their associations with certain symptoms of mixed connective tissue disease and systemic lupus erythematosus. The RNP is generally thought to be a ribonucleoprotein and there is evidence that its RNA may be single-stranded. Experiments presented in this report are in support of the concept that the Sm-antigen may also be an RNA protein. Purified Sm-anti-Sm precipitates were shown to have high RNA contents and treatment of Sm-antigen with RNAase in a hypotonic medium strongly reduced in antigenicity. The latter effect indicates that the Sm-antigen may in contrast to the RNP contain double-stranded RNA, a possibility also suggested by the finding that the Sm-antigen was soluble in 2 M LiCl. The Sm-antigen was found further to differ from RNP in being selectively absorbed in BD-Sephadex, while RNP remained active in the supernatant. Cytochemical studies involving stimulation and inhibition experiments with lectins and RNA polymerase inhibitors showed that the Sm-antigen was, in distinction to RNP, sensitive to rifampicin but not to alpha-amanitine. This suggests that the RNAs of the nucleoplasmic antigens may be synthesized by different RNA polymerases.

A monoclonal antibody specific for the major primary biliary cirrhosis (PBC)-associated mitochondrial antigen (subunit I of NADH-ubiquinone reductase) was produced and used to study the binding sites recognized by anti-mitochondrial autoantibodies (AMA) in PBC sera. Immunization of mice with purified beef heart mitochondrial inner membranes resulted in one monoclonal antibody which reacted with mitochondrial proteins. This antibody (PBC-MoAb), which was of the IgG2b subclass with kappa light chains, exhibited a pattern of immunofluorescence reactivity with rat kidney, human thyroid, and cultured human epithelial cells (Hep-2) similar to that obtained with sera from PBC patients. Similar binding patterns between PBC-MoAb and AMA were also found in western blot analysis using mitochondria as antigen. Both types of antibodies revealed a major antigen of 75 kDa, a minor antigen of 60 kDa, and a third antigen (70 kDa), which was detected only in samples that had not been boiled prior to electrophoresis. Furthermore, optimal binding of the PBC-MoAb and AMA to the 75 and 70 kDa antigens required reduction of the antigen with mercaptoethanol prior to electrophoresis. Competition ELISA experiments were conducted to compare the epitopes recognized by PBC-MoAb and AMA. Of 28 PBC sera tested, 27 inhibited the binding of PBC-MoAb to mitochondrial inner membranes by almost 100% and one serum inhibited binding by 50%, indicating that most PBC sera contain autoantibodies reactive with the same or a closely related antibody binding site as the PBC-MoAb. PBC-MoAb inhibited AMA binding to the inner membrane by more than 80% in 10 sera, 60-80% in 11 sera, and 40-59% in seven sera, with an average inhibition of 71%. Our observations strongly indicate that anti-mitochondrial autoantibody binding sites are restricted to a highly immunogenic epitope on the major PBC-specific antigen (NADH-ubiquinone reductase subunit I), and that the anti-mitochondrial monoclonal antibody obtained has a specificity identical with the human PBC-specific M2 type anti-mitochondrial autoantibody.